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The third sentence of the ‘‘Patient Disposition
and Demographics’’ subsection within the
‘‘Results’’ section should read:
‘‘For metformin and sulfonylurea, 72% and
74% of patients also had HbA1c assessed at
week 52.’’
The third paragraph of the ‘‘Predictive
Parameters’’ subsection within the ‘‘Results’’
section should read:
‘‘The predictive parameters for improvements
in HbA1c for week 24, based on the composite
unified early-response measure (reduction in
HbA1c level of C1.0% or HbA1c level of\7.0%)
for metformin were 0.83, 0.81, 0.44, and 0.96;
for sulfonylurea, 0.79, 0.94, 0.71, and 0.96; and
for insulin glargine, 0.67, 0.89, 0.65, and 0.90.’’
Within the footnote to Table 5, the optimal
early-response measure should be defined as:
‘‘HbA1c reduction of C1.0% for sulfonylurea
and glargine at week 24 and for sulfonylurea at
week 52, HbA1c reduction of C0.8% for
metformin at week 24, and HbA1c reduction of
C0.6% for metformin at week 52’’.
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